YM BioSciences Inc. is a biopharmaceutical company engaged in the development of products primarily for the treatment of patients with cancer. The Company owns or in-license substances or products in order to advance them along the regulatory and clinical pathways toward commercial approval. The Company’s portfolio of products in active clinical development includes one anti-cancer agent (a monoclonal antibody) in a number of clinical trials targeting more than 10 different tumors and/or stages of cancer, and an inhalation-delivery approach for fentanyl to treat acute pain, including cancer pain. The Company’s two product candidates in the clinical stage of development, as of June 30, 2009, were NIMOTUZUMAB and AeroLEF. Its three additional products licensed that are not in clinical development include Tesmilifene and two anti-cancer vaccines, a TGFα vaccine and a HER1-targeting vaccine.